The present disclosure pertains to the technical field of vitamin K2, and relates to a vitamin K2 microcapsule, a preparation method thereof, and use thereof in the manufacture of a medicament for preventing and treating cardiovascular and cerebrovascular diseases. The vitamin K2 microcapsule contains the following components by weight: 0.001 to 10 parts of vitamin K2, 5 to 30 parts of polyunsaturated fatty acid source, 0.1 to 10 parts of vitamin E-polyethylene glycol succinate, 50 to 95 parts of water-phase wall material and 0.01 to 10 parts of antioxidant, the polyunsaturated fatty acid source contains an ω-6 source and an ω-3 source, and the antioxidant is a water-phase antioxidant and/or an oil-phase antioxidant. The vitamin K2 microcapsule prepared by the method of the present disclosure has good water solubility, good stability and high bioavailability, can significantly improve the preventive and/or therapeutic effects on cardiovascular and cerebrovascular diseases, and has broad application prospects.

The invention relates to a capsule consisting of a shell and a filling, which contains plant sterol ester and/or plant stanol ester and emulsifier. The capsule is suitable for lowering serum LDL cholesterol level.

Active agent encapsulated with a protective composite coating is provided. The coating comprises a first hydrophilic water-swellable inner coating comprising a sealant agent combined with a plasticizer to coat particles of the active agent; and a second hydrophobic outer coating comprising a hydrophobic component combined with an enteric polymer and a plasticizer. The composite coating enhances the stability/viability of the active agent during prolonged storage prior to administration, and on exposure to harsh physiological conditions (e.g. gastric environment) following administration to permit enteric delivery of the active agent. A method of preparing the coated active agent is also provided.

A capsule containing total flavonoids of Desmodium styracifolium, a method for preparing the same and a use of the capsule containing total flavonoids of Desmodium styracifolium are provided. Specifically, the capsule includes total flavonoids of Desmodium Styracifolium provided in a form of alcohol extract of Desmodium Styracifolium and a pharmaceutically acceptable excipient.

Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.

The invention relates to compositions for vaginal or, alternatively, oral administration and to the use of such compositions for stabilizing the vaginal, or, alternatively, the intestinal acidity and establishing favorable conditions for the inhibition of pathogens and the growth of lactobacilli in the urogenital, or, alternatively, gastro-intestinal tract.

Disclosed are compositions and methods related to eukaryotic microorganisms that can produce unsaturated fatty acids which can be purified and used.

The present invention provides a method for producing a soft gel capsule comprising uncoated probiotic bacteria, the method comprising gentle mixing the uncoated probiotic bacteria with at least one oil to obtain a soft gel capsule fill material at a temperature in the range of 5 to 15° C., encapsulating the fill material in a soft gel capsule made of a gelatin having a melting point in the range of 11 to 28° C.; and drying the soft gel capsule in one or more steps to a water activity of at the most 0.25 at a temperature of at the most 25° C., as well as soft gel capsules produced by this method. The present invention further provides a soft gel capsule comprising dried, uncoated, non-spore-forming probiotic bacteria wherein the soft gel capsule comprises at least E+09 viable bacteria after 24 months of storage at 25° C., e.g. at least 2 E+09 viable bacteria after 12 months of storage at 25° C.

The patent discloses self-emulsifying formulations of bisphosphonates or bisphosphonic acids in the prevention and treatment of conditions involving calcium or phosphate metabolism. The dosage forms are either capsules, or tablets, or other controlled release drug delivery systems, or devices that contain self-emulsifying formulation of such bisphosphonates or bisphosphonic acids.

Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.